Eugene R. Worth

Eugene R. Worth, MD, M.Ed., FABA, ABPM/UHM is a board-certified anesthesiologist specialized in cardiac and vascular anesthesia. He is a wound care and hyperbaric physician, and Advisor/Editor of WoundReference, Inc., a clinical and reimbursement decision support platform for wound care and hyperbaric clinicians. Dr Worth is the recipient of a number of awards and distinctions in undersea and hyperbaric medicine. He has been a physician surveyor for the UHMS Accreditation Team and a reviewer for the journal, Undersea and Hyperbaric Medicine. He is a physician member of the UHMS Safety Committee. He has written multiple publications and book chapters for topics in hyperbaric medicine.

Articles by Eugene R. Worth

• Investigational HBOT indications: Inflammatory bowel disease

  Thursday, January 16, 2020

  It is time for the third installment of diseases that are considered "off-label" for hyperbaric oxygen...yet, these diseases have some evidence supporting effectivity and plausible pathophysiology for HBOT use. This blog installment will cover inflammatory bowel disease (IBD). Like our cardiac pre-conditioning blog, there will be a number of papers to consider. We are in luck because there are several "review articles" that have taken the literature to that point and reviewed or attempted to classify the research by effectivity.

• Investigational hyperbaric oxygen therapy indications: Preconditioning for cardiac surgery

  Thursday, December 12, 2019

  Welcome to another post on plausible, off-label uses for hyperbaric oxygen therapy. We have previously discussed the rationale for using hyperbaric oxygen therapy (HBOT) in an "off-label" indication. We suggested that there must be a scientific rationale, physiology that made sense for use of HBOT, and some sort of verified outcome (case report, case series, controlled clinical trial, etc.). Today, we are going to discuss the use of HBOT for patients who have an ischemia/reperfusion injury (IRI) to the myocardium.

• Investigational hyperbaric oxygen therapy indications: Infertility

  Thursday, November 21, 2019

  We have previously discussed the rationale for using hyperbaric oxygen therapy (HBOT) in an "off-label" indication. We suggested that there must be a scientific rationale, physiology that made sense for use of HBOT, and some sort of verified outcome. In this article, we will provide an update on use of HBOT as an adjunctive treatment for female infertility. Female infertility can be considered an off-label, plausible indication for HBOT. That is, there is some evidence supporting the use of HBOT for this indication; however, it is not an indication that is approved by the Undersea and Hyperbaric Medical Society (UHMS).

• Investigational hyperbaric oxygen therapy indications

  Thursday, November 07, 2019

  We would like to start this series by emphasizing that we are not recommending hyperbaric oxygen therapy (HBOT) for off-label indications. However, the use of HBOT for certain off-label conditions may be supported by some evidence, as described by case reports, case series, or small randomized controlled trials (RCTs). In this series, we will provide an overview of off-label indications for HBOT and review existing evidence for several conditions. We are going to start with an overview of off-label HBOT. To do so, we must define the boundaries of "on"- and "off"-label HBOT use.